Multiple-Dose Pharmacokinetics of the Selective Nicotinic Receptor Partial Agonist, Varenicline, in Healthy Smokers
- 1 December 2006
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 46 (12) , 1439-1448
- https://doi.org/10.1177/0091270006292624
Abstract
Curve from time zero to the end of the dosing interval val- ues were observed between the 1-mg and 2-mg daily doses of varenicline. Once- and twice-daily dosing resulted, on average, in an approximate 2- and 3-fold increase in varenicline systemic exposure, respectively, compared with single dose. There was no evidence of concentration- or time- dependent changes in the pharmacokinetics of varenicline upon repeat dosing.Keywords
This publication has 11 references indexed in Scilit:
- METABOLISM AND DISPOSITION OF VARENICLINE, A SELECTIVE α4β2 ACETYLCHOLINE RECEPTOR PARTIAL AGONIST, IN VIVO AND IN VITRODrug Metabolism and Disposition, 2006
- Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking CessationJournal of Medicinal Chemistry, 2005
- Metabolism and Disposition Kinetics of NicotinePharmacological Reviews, 2005
- Mortality in relation to smoking: 50 years' observations on male British doctorsBMJ, 2004
- Estimates of global mortality attributable to smoking in 2000The Lancet, 2003
- Trans‐3′‐hydroxycotinine: Disposition kinetics, effects and plasma levels during cigarette smokingBritish Journal of Clinical Pharmacology, 2001
- NICOTINE ADDICTIONPrimary Care: Clinics in Office Practice, 1999
- Pharmacology of Nicotine: Addiction and TherapeuticsAnnual Review of Pharmacology and Toxicology, 1996
- Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working PartyDrug Information Journal, 1995
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976